From October 1, 2026, United States global-health assistance runs on a new contract: under the America First Global Health Strategy, bilateral memoranda of understanding replace the grant machinery of the aid agency era, requiring partner governments to co-fund programmes and, in reported terms, to share patient data, accept American regulatory decisions without separate review, and in some negotiations discuss minerals and other returns, according to health-policy reporting on the rollout.
The scale is substantial — about 35 countries and roughly $14 billion over five years in the strategy’s reported design — and the flagship examples show the template. Rwanda’s agreement is reported at $157 million in American funding against $70 million Rwandan, with the data-sharing and regulatory-recognition provisions attached. Vietnam’s $98.75 million package, including a security component, continues HIV and tuberculosis work whose American funding has already tapered from about $98 million in 2010 to about $37 million in 2024. A parallel procurement mechanism offers up to $4.5 billion across as many as 100 awards, with individual country agreements reported from a few million to $180 million.
The refusals define the strategy as clearly as the signatures. Ghana, Namibia and Zimbabwe have declined or stalled on the reported terms; Ghana’s president described the offer at the United Nations General Assembly in September as humiliating in scale against what is asked, Zimbabwe’s funding has been halted following its refusal in late September, and Zambia’s talks are reported snagged on minerals provisions. A health agreement that arrives with a mining annex is, to its critics, no longer purely a health agreement — and the strategy’s defenders answer that burden-sharing and measurable returns are what make assistance survivable in an appropriations fight, which is the arena where the predecessor model died.
Timing exposes the strain. The new fiscal structure began October 1 while country implementation budgets were due October 2, and reporting describes the machinery as not yet on track in several capitals — the predictable friction of replacing a grant system with 35 simultaneous negotiations. Behind the diplomacy sits an administrative fact: about $2.5 billion was moved to a non-expiring account for the close-out of the former aid structure as the fiscal year ended September 30, the past paying for its own winding-down while the future negotiates its terms.
For the patients inside these programmes — HIV treatment cohorts, tuberculosis services, malaria supply chains — the strategy will be judged on continuity, not communiqués. Co-funding that arrives is better than grants that were cancelled; conditions that delay signatures interrupt the clinics either way. The memoranda are written. The medicines now have to be, too.
Related reading:
